Synthesis and evaluation of a radioiodinated bladder cancer specific peptide

Yeong Su Ha, Hwa Young Lee, Gwang Il An, Jonghee Kim, Wonjung Kwak, Eun Ju Lee, Seung Min Lee, Byung Heon Lee, In-San Kim, Takele Belay, Woonghee Lee, Byeong Cheol Ahn, Jaetae Lee, Jeongsoo Yoo

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Bladder cancer is the second most common cancer of the urinary tract, however the invasive cystoscopy is still the standard technique for diagnosis and surveillance of bladder cancer. Herein, we radiolabel bladder cancer specific peptide with radioactive iodine ( 131/124 I) and evaluate its potential as a new radiopharmaceutical for the non-invasive diagnosis of bladder cancer. A 9-mer bladder cancer specific peptide (BP) was conjugated with tyrosine and cyclized by disulfide bond formation to give Y-BP, which was further radioiodinated to give [ 131/124 I]Y-BP in good radiochemical yield. The biodistribution data showed the high selectivity of [ 124 I]Y-BP in HT1376 human bladder cancer xenograft models with a tumor-to-muscle ratio of 6.2. This tumor targeting was not observed in control B16F10 melanoma tumor models. In microPET studies, while the control scrambled peptide, [ 124 I]Y-sBP, did not accumulate in either the bladder cancer or melanoma, [ 124 I]Y-BP showed high tumor uptake only in animals with HT1376 bladder cancer cells. Furthermore, [ 124 I]Y-BP showed superior bladder cancer uptake even compared to most commonly used cancer imaging tracer, [ 18 F]FDG. The experimental results suggest the potential of [ 124 I]Y-BP as a new radiopharmaceutical for the non-invasive diagnosis of bladder cancer with high binding affinity and selectivity.

Original languageEnglish
Pages (from-to)4330-4335
Number of pages6
JournalBioorganic and Medicinal Chemistry
Volume20
Issue number14
DOIs
Publication statusPublished - 2012 Jul 15
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Tumors
Peptides
Radiopharmaceuticals
Heterografts
Iodine
Disulfides
Tyrosine
Muscle
Neoplasms
Animals
Cells
Melanoma
Imaging techniques
Urologic Neoplasms
Cystoscopy
Muscles

Keywords

  • Bladder cancer
  • Disease-specific peptide
  • PET
  • Radioiodination
  • Radiopharmaceuticals

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Cite this

Ha, Y. S., Lee, H. Y., An, G. I., Kim, J., Kwak, W., Lee, E. J., ... Yoo, J. (2012). Synthesis and evaluation of a radioiodinated bladder cancer specific peptide. Bioorganic and Medicinal Chemistry, 20(14), 4330-4335. https://doi.org/10.1016/j.bmc.2012.05.049

Synthesis and evaluation of a radioiodinated bladder cancer specific peptide. / Ha, Yeong Su; Lee, Hwa Young; An, Gwang Il; Kim, Jonghee; Kwak, Wonjung; Lee, Eun Ju; Lee, Seung Min; Lee, Byung Heon; Kim, In-San; Belay, Takele; Lee, Woonghee; Ahn, Byeong Cheol; Lee, Jaetae; Yoo, Jeongsoo.

In: Bioorganic and Medicinal Chemistry, Vol. 20, No. 14, 15.07.2012, p. 4330-4335.

Research output: Contribution to journalArticle

Ha, YS, Lee, HY, An, GI, Kim, J, Kwak, W, Lee, EJ, Lee, SM, Lee, BH, Kim, I-S, Belay, T, Lee, W, Ahn, BC, Lee, J & Yoo, J 2012, 'Synthesis and evaluation of a radioiodinated bladder cancer specific peptide', Bioorganic and Medicinal Chemistry, vol. 20, no. 14, pp. 4330-4335. https://doi.org/10.1016/j.bmc.2012.05.049
Ha, Yeong Su ; Lee, Hwa Young ; An, Gwang Il ; Kim, Jonghee ; Kwak, Wonjung ; Lee, Eun Ju ; Lee, Seung Min ; Lee, Byung Heon ; Kim, In-San ; Belay, Takele ; Lee, Woonghee ; Ahn, Byeong Cheol ; Lee, Jaetae ; Yoo, Jeongsoo. / Synthesis and evaluation of a radioiodinated bladder cancer specific peptide. In: Bioorganic and Medicinal Chemistry. 2012 ; Vol. 20, No. 14. pp. 4330-4335.
@article{ecb4c29a8c9549f19fe3bba4a59a5167,
title = "Synthesis and evaluation of a radioiodinated bladder cancer specific peptide",
abstract = "Bladder cancer is the second most common cancer of the urinary tract, however the invasive cystoscopy is still the standard technique for diagnosis and surveillance of bladder cancer. Herein, we radiolabel bladder cancer specific peptide with radioactive iodine ( 131/124 I) and evaluate its potential as a new radiopharmaceutical for the non-invasive diagnosis of bladder cancer. A 9-mer bladder cancer specific peptide (BP) was conjugated with tyrosine and cyclized by disulfide bond formation to give Y-BP, which was further radioiodinated to give [ 131/124 I]Y-BP in good radiochemical yield. The biodistribution data showed the high selectivity of [ 124 I]Y-BP in HT1376 human bladder cancer xenograft models with a tumor-to-muscle ratio of 6.2. This tumor targeting was not observed in control B16F10 melanoma tumor models. In microPET studies, while the control scrambled peptide, [ 124 I]Y-sBP, did not accumulate in either the bladder cancer or melanoma, [ 124 I]Y-BP showed high tumor uptake only in animals with HT1376 bladder cancer cells. Furthermore, [ 124 I]Y-BP showed superior bladder cancer uptake even compared to most commonly used cancer imaging tracer, [ 18 F]FDG. The experimental results suggest the potential of [ 124 I]Y-BP as a new radiopharmaceutical for the non-invasive diagnosis of bladder cancer with high binding affinity and selectivity.",
keywords = "Bladder cancer, Disease-specific peptide, PET, Radioiodination, Radiopharmaceuticals",
author = "Ha, {Yeong Su} and Lee, {Hwa Young} and An, {Gwang Il} and Jonghee Kim and Wonjung Kwak and Lee, {Eun Ju} and Lee, {Seung Min} and Lee, {Byung Heon} and In-San Kim and Takele Belay and Woonghee Lee and Ahn, {Byeong Cheol} and Jaetae Lee and Jeongsoo Yoo",
year = "2012",
month = "7",
day = "15",
doi = "10.1016/j.bmc.2012.05.049",
language = "English",
volume = "20",
pages = "4330--4335",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "14",

}

TY - JOUR

T1 - Synthesis and evaluation of a radioiodinated bladder cancer specific peptide

AU - Ha, Yeong Su

AU - Lee, Hwa Young

AU - An, Gwang Il

AU - Kim, Jonghee

AU - Kwak, Wonjung

AU - Lee, Eun Ju

AU - Lee, Seung Min

AU - Lee, Byung Heon

AU - Kim, In-San

AU - Belay, Takele

AU - Lee, Woonghee

AU - Ahn, Byeong Cheol

AU - Lee, Jaetae

AU - Yoo, Jeongsoo

PY - 2012/7/15

Y1 - 2012/7/15

N2 - Bladder cancer is the second most common cancer of the urinary tract, however the invasive cystoscopy is still the standard technique for diagnosis and surveillance of bladder cancer. Herein, we radiolabel bladder cancer specific peptide with radioactive iodine ( 131/124 I) and evaluate its potential as a new radiopharmaceutical for the non-invasive diagnosis of bladder cancer. A 9-mer bladder cancer specific peptide (BP) was conjugated with tyrosine and cyclized by disulfide bond formation to give Y-BP, which was further radioiodinated to give [ 131/124 I]Y-BP in good radiochemical yield. The biodistribution data showed the high selectivity of [ 124 I]Y-BP in HT1376 human bladder cancer xenograft models with a tumor-to-muscle ratio of 6.2. This tumor targeting was not observed in control B16F10 melanoma tumor models. In microPET studies, while the control scrambled peptide, [ 124 I]Y-sBP, did not accumulate in either the bladder cancer or melanoma, [ 124 I]Y-BP showed high tumor uptake only in animals with HT1376 bladder cancer cells. Furthermore, [ 124 I]Y-BP showed superior bladder cancer uptake even compared to most commonly used cancer imaging tracer, [ 18 F]FDG. The experimental results suggest the potential of [ 124 I]Y-BP as a new radiopharmaceutical for the non-invasive diagnosis of bladder cancer with high binding affinity and selectivity.

AB - Bladder cancer is the second most common cancer of the urinary tract, however the invasive cystoscopy is still the standard technique for diagnosis and surveillance of bladder cancer. Herein, we radiolabel bladder cancer specific peptide with radioactive iodine ( 131/124 I) and evaluate its potential as a new radiopharmaceutical for the non-invasive diagnosis of bladder cancer. A 9-mer bladder cancer specific peptide (BP) was conjugated with tyrosine and cyclized by disulfide bond formation to give Y-BP, which was further radioiodinated to give [ 131/124 I]Y-BP in good radiochemical yield. The biodistribution data showed the high selectivity of [ 124 I]Y-BP in HT1376 human bladder cancer xenograft models with a tumor-to-muscle ratio of 6.2. This tumor targeting was not observed in control B16F10 melanoma tumor models. In microPET studies, while the control scrambled peptide, [ 124 I]Y-sBP, did not accumulate in either the bladder cancer or melanoma, [ 124 I]Y-BP showed high tumor uptake only in animals with HT1376 bladder cancer cells. Furthermore, [ 124 I]Y-BP showed superior bladder cancer uptake even compared to most commonly used cancer imaging tracer, [ 18 F]FDG. The experimental results suggest the potential of [ 124 I]Y-BP as a new radiopharmaceutical for the non-invasive diagnosis of bladder cancer with high binding affinity and selectivity.

KW - Bladder cancer

KW - Disease-specific peptide

KW - PET

KW - Radioiodination

KW - Radiopharmaceuticals

UR - http://www.scopus.com/inward/record.url?scp=84863212261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863212261&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2012.05.049

DO - 10.1016/j.bmc.2012.05.049

M3 - Article

C2 - 22705190

AN - SCOPUS:84863212261

VL - 20

SP - 4330

EP - 4335

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 14

ER -